FibroGen

company

About

FibroGen, a research-based biotech firm, uses its expertise CTGF and HIF biology to discover, develop, and commercialize novel therapeutics.

  • 251 - 500

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$62M
Industries
Biopharma,Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 1993
Number Of Employee
251 - 500
Operating Status
Active

FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$162M
FibroGen has raised a total of $162M in funding over 2 rounds. Their latest funding was raised on Jul 8, 2016 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 8, 2016 Post-IPO Equity $62M 1 AstraZeneca Detail
Feb 17, 2005 Series Unknown $100M 3 Detail

Investors

Number of Lead Investors
Number of Investors
1
4
FibroGen is funded by 4 investors. AstraZeneca and Corriente Biotechnology Partners are the most recent investors.
Investor Name Lead Investor Funding Round
AstraZeneca Yes Post-IPO Equity
Corriente Biotechnology Partners Series Unknown
Apothecary Capital Series Unknown
Daiwa SMBC Capital Series Unknown